EDNRA and pulmonary arterial hypertension: The newest non-peptide drug, Macitentan, was approved by European Medicines Agency (EMA) and the FDA for long-term management of PAH, which has high tissue targeting with sustained receptor binding and 50-fold higher affinity for ETA than ETB receptors [17].